var data={"title":"Ulipristal: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ulipristal: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/427390?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ulipristal-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ulipristal: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51222933\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Fibristal Safety Alert</span>\n      <span class=\"collapsible-date\">March 2018</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Health Canada is conducting a safety review of <span class=\"trade-name\">Fibristal</span> (ulipristal acetate) due to reports of serious adverse effects affecting the liver. The Canadian label for <span class=\"trade-name\">Fibristal</span> was updated in January 2018 warning of rare cases of liver injury, including serious liver impairment requiring liver transplants. Health Canada will review all currently available information, including scientific and medical literature as well as Canadian and international cases of liver injury.</p>\n        <p style=\"text-indent:0em;\">Health care professionals should discuss the benefits and risks of <span class=\"trade-name\">Fibristal</span> with patients, and it should not be prescribed in patients with active/concomitant hepatic disease. Patients' liver function should be monitored at least once a month during treatment or as clinically indicated, and 2 to 4 weeks after treatment completion.</p>\n        <p style=\"text-indent:0em;\">More information is available at http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2018/66210a-eng.php.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10519685\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Ella</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21303676\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Ella;</li>\n      <li>Fibristal</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10519806\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Contraceptive;</li>\n      <li>\n        Progestin Receptor Modulator</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10579713\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Emergency contraception (Ella):</b> Oral: 30 mg as soon as possible, but within 120 hours (5 days) of unprotected intercourse or contraceptive failure.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Uterine fibroids (Fibristal [Canadian product]):</b> Females (premenopausal): Oral: 5 mg once daily for 3 consecutive months (each course of therapy is limited to 3 months). Initiate the first treatment course within the first 7 days of menstruation; initiate subsequent treatment courses, at the earliest, the first week of the second menstruation following completion of the prior treatment course. The recommended treatment-free interval between treatment courses is 2 menstrual cycles. Repeated intermittent treatment has been studied up to 4 intermittent courses.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10579712\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Emergency contraception (Ella):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children and Adolescents (prepubertal): Not indicated for use prior to menarche.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adolescents (postpubertal): Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10579714\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Not indicated for use in postmenopausal women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22815718\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied); however, dosage adjustment may not be necessary since renal elimination of ulipristal is minimal (Pohl 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22815719\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ella:</b> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Fibristal [Canadian product]:</b> No dosage adjustment necessary in mild or moderate impairment; has not been studied in severe impairment (monitor closely if initiating therapy).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11285145\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as acetate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ella: 30 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10579629\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21303792\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, Oral, as acetate:</p>\n    <p style=\"text-indent:2em;\">Fibristal: 5 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10579748\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ella: Administer with or without food at anytime during menstrual cycle. If vomiting occurs within 3 hours of administration, consider repeating dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fibristal [Canadian product]: Administer with water and with or without food; initiate during the first 7 days of menstrual cycle.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49104601\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 3]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10519808\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Emergency contraceptive (Ella):</b> Prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure. Ulipristal is not intended for routine use as a contraceptive.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Uterine fibroids (Fibristal [Canadian product]):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Treatment of moderate to severe signs/symptoms of uterine fibroids in adult women of reproductive age who are eligible for surgery.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intermittent treatment of moderate to severe signs/symptoms of uterine fibroids in adult women of reproductive age</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10579628\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Ulipristal may be confused with ursodiol</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10579636\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Emergency contraception (Ella):</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (18% to 19%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Suppressed menstruation (&ge;7 days later than expected: 19%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain (8% to 15%), nausea (12% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Dysmenorrhea (7% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (6%), dizziness (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Intermenstrual bleeding (9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Early menses (&ge;7 days earlier than expected: 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Postmarketing and/or case reports: Acne vulgaris</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Treatment of moderate-to-severe signs/symptoms of uterine fibroids (Fibristal [Canadian product]):</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (1% to 16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hot flash (1% to 25%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Edema (&le;1%), hypotension (&le;1%), sinus bradycardia (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (&le;4%), vertigo (&le;4%), insomnia (&le;2%), dizziness (1%), aggressive behavior (&le;1%), drowsiness (&le;1%), emotional lability (&le;1%), migraine (&le;1%), sleep disorder (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Night sweats (&le;2%), acne vulgaris (&le;1%), alopecia (&le;1%), seborrhea (&le;1%), xeroderma (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypercholesterolemia (3%), hypertriglyceridemia (&le;3%), hypothyroidism (&le;2%), obesity (1%), amenorrhea (&le;1%), increased gamma-glutamyl transferase (&le;1%), ovarian cyst (&le;1%), ovarian hyperstimulation (&le;1%), thyroid disease (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (3%), constipation (1%), dyspepsia (&le;1%), upper abdominal pain (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Mastalgia (2%), pelvic pain (1% to 2%), endometrial hyperplasia (&le;2%), genital bleeding (&le;2%), breast swelling (&le;1%), breast tenderness (&le;1%), genital discharge (&le;1%), uterine disease (&le;1%), uterine hemorrhage (&le;1%), vaginal dryness (&le;1%), vulvovaginal candidiasis (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Herpes virus infection (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (2%), muscle spasm (&le;2%), back pain (&le;1%), limb pain (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea (&le;1%), epistaxis (&le;1%), pharyngitis (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (&le;1%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10579633\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ella: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>US labeling:</i> Known or suspected pregnancy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Canadian labeling: </i>Hypersensitivity to ulipristal or any component of the formulation; known or suspected pregnancy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fibristal [Canadian product]: Hypersensitivity to ulipristal or any component of the formulation; pregnancy; breast-feeding; genital bleeding of unknown etiology or for reasons other than uterine fibroids; cancer of the breast, cervix, uterus, or ovaries</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10579634\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding irregularities: Menstrual bleeding patterns may be altered (cycle length may be delayed or shortened by a few days), but returns to normal in subsequent cycles. Intermenstrual bleeding (spotting) has also been observed. The possibility of pregnancy should be considered if menstruation is delayed for &gt;7 days of the expected menstrual period. In the treatment of uterine fibroids with Fibristal [Canadian product], a significant reduction in menstrual blood loss or amenorrhea is usually observed within 10 days of initiation; menses generally returns within 4 weeks after discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Endometrial thickening: Endometrial thickening has been observed with use of Fibristal [Canadian product] in the treatment of uterine fibroids; effects are reversible following discontinuation of therapy. Persistent endometrial thickening (&gt;3 months after discontinuation of therapy and return of menses) should be further evaluated. Changes in endometrial tissue observed with use are referred to as progesterone receptor modulator-associated endometrial changes (PAEC); may be mistaken for endometrial hyperplasia. Pathologists should be informed of ulipristal therapy when submitting endometrial tissue for histologic evaluation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Asthma: Fibristal [Canadian product] is not recommended in patients with severe uncontrolled asthma.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Not for use prior to menarche.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Postmenopausal women: Not indicated for use in postmenopausal women.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Not intended for routine contraception. Repeated use within the same menstrual cycle is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ectopic pregnancy: A history of ectopic pregnancy is not a contraindication to use in emergency contraception. The possibility of ectopic pregnancy should be considered in patients if pregnancy occurs after treatment or in patients with lower abdominal pain after administration of ulipristal.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fertility: A return of fertility is likely to be rapid following treatment of ulipristal for emergency contraception. Efficacy of hormonal contraception may be decreased; hormonal contraception should not be initiated until &ge;5 days after emergency contraception and barrier contraception is recommended immediately following use of ulipristal; barrier contraception should be continued throughout the same menstrual cycle. Any nonhormonal contraceptive may be started immediately after uliprstal (Curtis 2016a). A nonhormonal method of contraception is recommended for women receiving Fibristal [Canadian product] for the treatment of uterine fibroids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; HIV infection protection: Does not protect against HIV infection or other sexually-transmitted diseases.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pregnancy: Use is contraindicated in patients known or suspected to be pregnant. Exclude pregnancy prior to therapy via history, physical exam or pregnancy testing; not indicated for terminating an existing pregnancy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300192\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11304727\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=15626&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May decrease the serum concentration of Ulipristal.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of Ulipristal.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of Ulipristal.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Ulipristal. Management: This is specific for when ulipristal is being used for signs/symptoms of uterine fibroids (Canadian indication). When ulipristal is used as an emergency contraceptive, patients receiving this combination should be monitored for ulipristal toxicity.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Ulipristal. Management: This is specific for when ulipristal is being used for signs/symptoms of uterine fibroids (Canadian indication). When ulipristal is used as an emergency contraceptive, patients receiving this combo should be monitored for ulipristal toxicity.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Efavirenz: May decrease the serum concentration of Ulipristal.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Felbamate: May decrease the serum concentration of Ulipristal.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Griseofulvin: May decrease the serum concentration of Ulipristal.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OXcarbazepine: May decrease the serum concentration of Ulipristal.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins: May diminish the therapeutic effect of Ulipristal. Ulipristal may diminish the therapeutic effect of Progestins. Management: Ulipristal for uterine fibroids (Canadian indication): avoid progestins within 12 days of stopping ulipristal; as emergency contraceptive (U.S. indication): avoid progestins within 5 days of stopping ulipristal.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of Ulipristal.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topiramate: May decrease the serum concentration of Ulipristal.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10579630\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">X (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10579631\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events have been observed in some animal reproduction studies. Exclude pregnancy prior to therapy; not indicated for terminating an existing pregnancy. A rapid return of fertility is expected following use for emergency contraception; routine contraceptive measures should be initiated or continued following use to ensure ongoing prevention of pregnancy. Barrier contraception is recommended immediately following emergency contraception and throughout the same menstrual cycle; efficacy of hormonal contraceptives may be decreased. The manufacturer labeling suggests that hormonal contraceptives may be less effective in females with BSA &gt;30 kg/m<sup>2</sup>. When ulipristal is used for treatment of uterine fibroids (Canadian labeling; not in US labeling) a nonhormonal method of contraception is recommended.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Health care providers are encouraged to enroll women who were exposed to ulipristal during the cycle pregnancy started or anytime during pregnancy in the Ellipse II study (forms available at www.ellipse2.com).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F18881610\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Ulipristal is excreted in breast milk. Following a single dose, mean breast milk concentrations within the first 24 hours were 22.7 ng/mL (ulipristal) and 4.49 ng/mL (active metabolite). Ulipristal concentrations decreased to less than 1 ng/mL by 96 to 120 hours after the dose, and were less than 1 ng/mL 24 to 48 hours after the dose for the active metabolite. Breastfeeding is not recommended by the manufacturer. Ulipristal may be used for emergency contraception in breastfeeding women, however, breast milk should be discarded for 24 hours after the dose (Curtis 2016b).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10579750\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Evaluate for pregnancy or ectopic pregnancy if expected menses is delayed for &ge;1 week following emergency contraception, or if lower abdominal pain (3 to 5 weeks after administration) or persistent irregular bleeding develops. A pregnancy test is recommended if withdrawal bleeding does not occur within 3 weeks following use as an emergency contraceptive (Curtis 2015a).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fibristal [Canadian product]: Rule out pregnancy prior to therapy initiation; periodic monitoring of the endometrium; unexpected or persistent irregular bleeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10579744\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Prevents progestin from binding to the progesterone receptor. Ulipristal postpones follicular rupture when administered prior to ovulation, thereby inhibiting or delaying ovulation. May also alter the normal endometrium, impairing implantation. When used for the treatment of signs and symptoms of uterine fibroids, ulipristal reduces the size of uterine fibroids by inhibiting cellular proliferation and inducing apoptosis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10579706\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Rapid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Ulipristal: &gt;98% to plasma proteins including albumin, alpha<sub>1</sub>-acid glycoprotein,  high-density lipoprotein, and low-density lipoprotein</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via CYP3A4; forms monodemethylated metabolite (active) and inactive metabolites</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Ulipristal: ~32 to 38 hours; Monodemethylated metabolite: ~27 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: 1 hour (ulipristal and monodemethylated metabolite)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces (primary route of elimination); urine (&lt;10%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322864\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Ella Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (1): $42.90</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11390247\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>5X (BD);</li>\n      <li>Duella (UA);</li>\n      <li>ella (BB, HK);</li>\n      <li>Ella (IL, MY, SG);</li>\n      <li>ellaOne (AT, BE, CH, CY, CZ, DE, DK, EE, ES, FR, GB, HN, HR, IE, KR, LB, LT, LU, LV, NL, NO, PL, PT, RO, SE, SI, SK, TR);</li>\n      <li>Esmiya (UA);</li>\n      <li>Esmya (AR, CH, CL, CR, DE, DO, EC, GB, GT, HK, HN, IE, LU, LV, MT, MY, NI, PA, PE, PH, SG, SV);</li>\n      <li>Femelle One (MX);</li>\n      <li>Inisia (KR);</li>\n      <li>Peuli (BD);</li>\n      <li>Post Day Plus (EC);</li>\n      <li>Postday Plus (CO);</li>\n      <li>Tulip (BD);</li>\n      <li>Uliroid (BD);</li>\n      <li>Utal (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27467319\"></a>Curtis KM, Jatlaoui TC, Tepper NK, et al. US selected practice recommendations for contraceptive use, 2016. <i>MMWR Recomm Rep</i>. 2016a;65(4):1&#8208;66. doi: 10.15585/mmwr.rr6504a1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ulipristal-drug-information/abstract-text/27467319/pubmed\" target=\"_blank\" id=\"27467319\">27467319</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27467196\"></a>Curtis KM, Tepper NK, Jatlaoui TC, et al. US medical eligibility criteria for contraceptive use, 2016. <i>MMWR Recomm Rep</i>. 2016b;65(3):1&#8208;103. doi: 10.15585/mmwr.rr6503a1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ulipristal-drug-information/abstract-text/27467196/pubmed\" target=\"_blank\" id=\"27467196\">27467196</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Donnez J, Tatarchuk TF, Bouchard P, et al, &ldquo;Ulipristal acetate versus placebo for fibroid treatment before surgery,&rdquo; <i>N Engl J Med</i>, 2012, 366(5):409-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ulipristal-drug-information/abstract-text/22296075/pubmed\" target=\"_blank\" id=\"22296075\">22296075</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ella (ulipristal) [prescribing information]. Charleston, SC: Afaxys Inc; March 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ella (ulipristal) [product monograph]. Mississauga, Ontario, Canada: Actavis Specialty Pharmaceuticals Co; January 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fibristal (ulipristal) [product monograph]. Markham, Ontario, Canada: Allergan Pharma Co; January 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fine P, Math&eacute; H, Ginde S, et al, &ldquo;Ulipristal Acetate Taken 48-120 Hours After Intercourse for Emergency Contraception,&rdquo;<i>Obstet Gynecol</i>, 2010, 115(2 Pt 1):257-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ulipristal-drug-information/abstract-text/20093897/pubmed\" target=\"_blank\" id=\"20093897\">20093897</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Glasier AF, Cameron ST, Fine PM, et al, &ldquo;Ulipristal Acetate Versus Levonorgestrel for Emergency Contraception: A Randomised Non-Inferiority Trial And Meta-Analysis,&rdquo; <i>Lancet</i>, 2010, 375(9714):555-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ulipristal-drug-information/abstract-text/20116841/pubmed\" target=\"_blank\" id=\"20116841\">20116841</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pohl O, Kendrick J, Gotteland JP. Metabolic disposition of [14C] ulipristal acetate in healthy premenopausal women. <i>J Bioequiv Availab.</i> 2013;5(4):177-184.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Preshaw PM. Oral contraceptives and the periodontium. <i>Peridontol 2000.</i> 2013;61(1):125-159.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ulipristal-drug-information/abstract-text/23240947/pubmed\" target=\"_blank\" id=\"23240947\">23240947</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 15626 Version 135.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F51222933\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F10519685\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F21303676\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F10519806\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F10579713\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F10579712\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F10579714\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F22815718\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22815719\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F11285145\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F10579629\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F21303792\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F10579748\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49104601\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F10519808\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F10579628\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F10579636\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F10579633\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F10579634\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300192\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F11304727\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F10579630\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F10579631\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F18881610\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F10579750\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F10579744\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F10579706\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322864\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F11390247\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/15626|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ulipristal-patient-drug-information\" class=\"drug drug_patient\">Ulipristal: Patient drug information</a></li></ul></div></div>","javascript":null}